These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16385903)

  • 1. The structural error-in-equation model to evaluate individual bioequivalence.
    Carrasco JL; Jover L
    Biom J; 2005 Oct; 47(5):623-34. PubMed ID: 16385903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An alternative approach to assess exchangeability of a test treatment and the standard treatment with normally distributed response.
    Tsong Y; Shen M
    J Biopharm Stat; 2007; 17(2):329-38. PubMed ID: 17365227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On population and individual bioequivalence.
    Schall R; Luus HG
    Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of the likelihood approach to bioequivalence trials.
    Choi L; Caffo B; Rohde C
    Stat Med; 2008 Oct; 27(24):4874-94. PubMed ID: 18618422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar.
    Schall R
    Biometrics; 1995 Jun; 51(2):615-26. PubMed ID: 7662849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Approach to Testing for Average Bioequivalence Based on Modeling the Within-Period Dependence Structure.
    Chandrasekhar R; Shi Y; Hutson AD; Wilding GE
    J Biopharm Stat; 2015; 25(6):1320-38. PubMed ID: 25671781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs.
    Jaki T; Pallmann P; Wolfsegger MJ
    Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fieller's confidence intervals for the ratio of two means in the assessment of average bioequivalence from crossover data.
    Vuorinen J; Tuominen J
    Stat Med; 1994 Dec 15-30; 13(23-24):2531-45. PubMed ID: 7701152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A note on statistical methods for assessing therapeutic equivalence.
    Chow SC; Shao J
    Control Clin Trials; 2002 Oct; 23(5):515-20. PubMed ID: 12392865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of missing data on type 1 error rates in non-inferiority trials.
    Yoo B
    Pharm Stat; 2010; 9(2):87-99. PubMed ID: 19408241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bayesian bias correction method of the first-order approximation of nonlinear mixed-effects models for population pharmacokinetics.
    Funatogawa T; Funatogawa I
    J Biopharm Stat; 2007; 17(3):381-92. PubMed ID: 17479388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified Wald test for reference scaled assessment of analytical equivalence.
    Weng YT; Tsong Y; Shen M; Wang C
    J Biopharm Stat; 2019; 29(6):1068-1081. PubMed ID: 30829123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inference of equivalence for the ratio of two normal means with unspecified variances.
    Xu S; Hua SY; Menton R; Barker K; Menon S; D'Agostino RB
    J Biopharm Stat; 2014; 24(6):1264-79. PubMed ID: 25033269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.